GlassScriptPhysician profile
Louis A Smith
NPI 1679519292
$3,874.58
in general payments reported to CMS, 2019-2025
33 companies · $28.91 in 2025
The $28.91 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,241 · 2020: $470 · 2021: $868 · 2022: $664 · 2023: $330 · 2024: $273 · 2025: $28.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $651.06 | 2019-2022 | |
| Abbott Laboratories | $567.22 | 2022-2025 | Freestyle Libre 3, Eterna |
| Abbvie INC. | $397.12 | 2019-2024 | Vraylar |
| Pfizer INC. | $289.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $261.74 | 2019-2022 | |
| Astellas Pharma US INC | $229.03 | 2019-2025 | Veozah |
| Novo Nordisk INC | $213.09 | 2019-2022 | |
| Amarin Pharma, INC. | $142.49 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $130.43 | 2019-2022 | |
| Glaxosmithkline, LLC. | $112.88 | 2021-2024 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.04 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $79.51 | 2019-2020 | |
| Esperion Therapeutics, INC. | $73.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $72.08 | 2019-2022 | |
| Lilly USA, LLC | $71.24 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $68.73 | 2021 | |
| Daiichi Sankyo INC. | $65.06 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $45.77 | 2019-2021 | |
| Genentech USA, INC. | $41.91 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.77 | 2019-2022 | |
| Horizon Therapeutics Plc | $28.97 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $27.39 | 2021 | |
| Inspire Medical Systems, INC. | $25.36 | 2023 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $24.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $24.46 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.71 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.73 | 2021 | |
| Allergan, INC. | $13.56 | 2019 | |
| Boston Scientific Corporation | $13.39 | 2023 | |
| Medtronic, INC. | $12.97 | 2021 | |
| Shire North American Group INC | $12.29 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.